Moreover, serum YKL-40 was not related to β-blocker (P = 0.273), calcium channel blockers (P = 0.296), statin or other lipid-lowering therapy (P = 0.061), or ACEI or ARB (P = 0.186) in CHD patients (Supplementary Table S2). This evidence concerns the gene CHI3L1 and coronary artery disorder.